Horizon Technology Finance, an affiliate of Monroe Capital, provided a $35 million venture loan facility to Onkos Surgical, of which $30 million has been initially funded.

Onkos intends to use the proceeds of the loan facility to accelerate manufacturing and commercialization of NanoCept™, a groundbreaking, antibacterial coating technology that is used on FDA-granted orthopaedic implants to reduce bacterial contamination at the time of implantation. Bacterial contamination of implants is a significant clinical challenge that can have devastating implications for patients and poses a substantial financial burden to the healthcare system.

“Onkos Surgical is disrupting the orthopaedic marketplace with a suite of differentiated products, including NanoCept,” said Gerald A. Michaud, President of Horizon. “We are pleased to support the growth of Onkos as it continues to innovate novel solutions that address diverse unmet needs in a growing and important market segment.”

Onkos Surgical is a leading innovator in the musculoskeletal space, developing technologies to address the clinical challenges associated with complex orthopaedic procedures.